Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies

Blood. 2008 Nov 15;112(10):4354-5; author reply 4355-6. doi: 10.1182/blood-2008-07-171082.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Animals
  • Antibodies, Monoclonal / genetics
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody-Dependent Cell Cytotoxicity / genetics
  • Antibody-Dependent Cell Cytotoxicity / immunology*
  • Antigens, CD20 / immunology*
  • Antigens, CD20 / metabolism
  • Antineoplastic Agents / immunology
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology*
  • Complement Activation / drug effects*
  • Complement Activation / genetics
  • Complement Activation / immunology
  • Complement C1q / immunology
  • Complement C1q / metabolism
  • Drug Evaluation, Preclinical / methods
  • Humans
  • Immunoglobulin Constant Regions / genetics
  • Immunoglobulin Constant Regions / immunology
  • Lymphocyte Depletion / methods*
  • Mutation, Missense
  • Protein Binding / genetics
  • Protein Binding / immunology
  • Receptors, IgG / genetics
  • Receptors, IgG / immunology
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • FcgammaRIIIA protein, mouse
  • Immunoglobulin Constant Regions
  • Receptors, IgG
  • Rituximab
  • Complement C1q